Used as an intermediate in the synthesis of antiviral agents, particularly NS5A inhibitors targeting hepatitis C virus (HCV). Its unique structure, featuring 6-methoxyquinolin-4-yl and 5-vinylquinuclidin-2-yl moieties linked by a phosphoramidate group, enables structural modifications to enhance inhibition of the viral NS5A enzyme. The phosphoramidate moiety supports incorporation into prodrug strategies, improving cellular uptake, metabolic activation, bioavailability, and targeted delivery to liver tissues. Commonly applied in pharmaceutical research for HCV and other viral disease treatments. Also utilized in medicinal chemistry for optimizing antiviral potency and reducing off-target effects.